本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Prime Medicine, Inc.

3.42
-0.1700-4.74%
盤後3.460.0400+1.17%18:42 EST
成交量:148.53萬
成交額:519.13萬
市值:6.17億
市盈率:-2.38
高:3.65
開:3.57
低:3.40
收:3.59
52周最高:6.94
52周最低:1.11
股本:1.81億
流通股本:9,979.87萬
量比:0.46
換手率:1.49%
股息:- -
股息率:- -
每股收益(TTM):-1.4387
每股收益(LYR):-1.6516
淨資產收益率:-112.34%
總資產收益率:-35.52%
市淨率:3.81
市盈率(LYR):-2.07

資料載入中...

公司資料

公司名字:
Prime Medicine, Inc.
交易所:
NASDAQ
成立時間:
2019
員工人數:
214
公司地址:
60 First Street,Cambridge,Massachusetts,United States
郵編:
02141
電話:
傳真:
- -
簡介:
Prime Medicine, Inc.於2019年9月在特拉華州註冊成立。該公司是一家生物技術公司,致力於提供一類新的差異化一次性治療基因療法— Prime Editors,通過部署Prime Editing技術來解決最廣泛的疾病譜。

董事

名稱
職位
Jeffrey D. Marrazzo
Executive Chairman of the Board
David Schenkein
Independent Director
Kaye Foster
Independent Director
Michael Kelly
Independent Director
Robert Taylor NELSEN
Independent Director
Thomas Cahill
Independent Director
Wendy Chung
Independent Director

股東

名稱
職位
Allan Reine
Chief Executive Officer and Chief Financial Officer
Carman Alenson
Senior Vice President, Finance and Chief Accounting Officer
Meredith Goldwasser
Senior Vice President, Strategy and Corporate Operations
Andrew Anzalone
Head of Prime Editing Platform
Ann Lee
Chief Technical Officer
Jeffrey D. Marrazzo
Executive Chairman of the Board
Richard Brudnick
Chief Business Officer